Search clinical trials for: AC-201

Total 4079 results

TWi Biotechnology, Inc.

Completed

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Taiwan
MedImmune LLC
AstraZeneca

Completed

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (FluMist)

Healthy | Influenza

United States
TWi Biotechnology, Inc.

Completed

A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Gout

Taiwan
TWi Biotechnology, Inc.

Completed

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

Inherited Epidermolysis Bullosa

Taiwan
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Chang Gung Memorial Hospital

Completed

Nonoperative Management Protocol in Patients With Blunt Splenic Injuries

Blunt Injuries
Duke University
Centers for Disease Control and Prevention; Children's Hospital Medical Center...

Completed

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (Tdap/IIV)

Pregnancy

United States
TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
TWi Biotechnology, Inc.

Recruiting

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Generalized Epidermolysis Bullosa Simplex

United States, Taiwan, Australia, Philippines
Cerecin

Terminated

Tricaprilin Liquid Formulation PK Study

Alzheimer Disease

Australia
Cerecin

Completed

Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production

Alzheimer Disease

Australia
TWi Biotechnology, Inc.

Completed

A Proof-of-Concept Study of AC-201 to Prevent Gout Flares

Gout Flares

Taiwan
Cerecin

Withdrawn

Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides

Alzheimer Disease
University of Maryland, Baltimore
National Institute on Aging (NIA); Penn State University

Recruiting

Implementation of Function Focused Care in Acute Care

Dementia | Hospitalization | Acute Medical Event

United States
Chang Gung Memorial Hospital
New Bellus Enterprises

Unknown

Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy

Neoplasm | Functional Gastrointestinal Disorder

Taiwan
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-208

Androgenetic Alopecia

Korea, Republic of
Addpharma Inc.

Not yet recruiting

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Hypertension,Essential

Korea, Republic of
Cerecin

Completed

Tricaprilin Phase 2 Pilot Study in Migraine

Migraine

Australia
Cerecin
Celerion

Completed

Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production

Healthy

United States
Cerecin
Celerion

Completed

Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production

Healthy

United States
Johns Hopkins University

Terminated

Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy

Diabetic Retinopathy | Stargardt Disease | Macular Degeneration (Age Related)

United States
Cerecin

Completed

Tricaprilin in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Cerecin

Completed

Tricaprilin In Age-Associated Memory Impairment

Age-Associated Memory Impairment

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Follow-up in Pediatric Intensive Care Unit (APRELAREA)

Intensive Care Psychosis

France
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
Boehringer Ingelheim

Completed

Bioequivalence Study of UH-AC 62 XX Tablets Compared With the Capsule Formulations in Healthy Volunteers

Healthy
Mỹ Đức Hospital

Recruiting

Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (FET-ADE)

Adenomyosis | Frozen Embryo Transfer | IVF

Vietnam
Cerecin

Withdrawn

A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension

Alzheimer's Disease
Arizona State University
Calm.com, Inc.

Completed

Incentivizing Meditation App Habit Formation

Stress | Adherence, Treatment

United States
TWi Biotechnology, Inc.

Completed

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

EGFR Inhibitor-Induced Skin Rash

Taiwan
Canopy Growth Corporation

Completed

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Delayed Onset Muscle Soreness (DOMS)

United States
TWi Biotechnology, Inc.

Completed

A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy

Hemophilic Arthropathy

Taiwan
Idorsia Pharmaceuticals Ltd.

Completed

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders

Healthy Subjects

Germany
University of Pittsburgh

Recruiting

Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community (Doulas-AC)

Metastatic Breast Cancer

United States
Cerecin

Completed

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH-AD)

Alzheimer's Disease

United States
Idorsia Pharmaceuticals Ltd.

Terminated

A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

Healthy Subjects

United Kingdom
CardioFocus

Completed

Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic AF

Paroxysmal Atrial Fibrillation

Germany
TruDiagnostic
Optigenex, Inc

Active, not recruiting

AC-11 Supplement and Biological Aging

Aging

United States
University of Minnesota
National Institute on Aging (NIA)

Completed

Comprehensive Support for Alzheimer's Disease Caregivers

Depression | Stress | Caregivers

United States
Addpharma Inc.

Completed

Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012

Hypertension | Hyperlipidemias

Korea, Republic of
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Johns Hopkins University

Completed

Biomarkers In Retinitis Pigmentosa (BIRP) (BIRP)

Retinitis Pigmentosa

United States
Cerecin

Active, not recruiting

Tricaprilin Infantile Spasms Pilot Study

Infantile Spasm

Singapore, Australia
DongGuk University
Korea Health Industry Development Institute

Unknown

Efficacy and Safety of Electroacupuncture and Acupuncture in Postmenopausal Women With Overactive Bladder

Overactive Bladder | Menopause

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
Aciex Therapeutics, Inc.

Completed

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

Allergic Conjunctivitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (GRC90)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India

3

Subscribe